Table 4. Baseline factors associated with in-hospital mortality in patients treated with HCQ.
| Univariate logistic regression | Multivariate logistic regression | |||
|---|---|---|---|---|
| Variable | Odds ratio (95% CI) | P | Adjusted odds ratio (95% CI) | P |
| Age, per year increase | 1.06 (1.03–1.10) | <0.001 | 1.06 (1.03–1.10) | 0.001 |
| Cerebrovascular disease | 4.24 (1.13–15.78) | 0.031 | 3.52 (0.79–15.64) | 0.098 |
| COPD | 5.30 (1.49–18.13) | 0.010 | Removed from final model1 | |
| Invasive mechanical ventilation | 2.38 (1.05–5.41) | 0.038 | Removed from final model1 | |
| Leukocytosis (white blood cell count > 10x109 cells/μL) | 6.73 (2.53–17.90) | <0.001 | 5.42 (1.88–15.63) | 0.002 |
| Azithromycin therapy2 | 1.07 (0.39–2.95)3 | 0.79 | Removed from final model4 | |
Abbreviation: COPD, chronic obstructive pulmonary disease.
1This variable was removed from the final multivariate model because its corresponding P value in the multivariate model was ≥0.2.
2Azithromycin used for ≥3 days and administered at the same time that HCQ was initiated.
3For comparison, the unadjusted odds ratio of in-hospital mortality was 1.43 (95% CI 0.61–3.34) for ceftriaxone therapy and 0.91 (95% CI 0.28–2.97) for doxycycline therapy.
4In an alternate multivariate model where azithromycin therapy was retained (with older age, cerebrovascular disease, and leukocytosis), the adjusted odds ratio for in-hospital mortality with azithromycin therapy was 1.14 (95% CI 0.37–3.49).